Zimbabwe has declined a major US health deal worth 367 million US dollars (£272m) over five years due to Washington's request for sensitive biological samples.
This rejection became public following a government memo from December was leaked, revealing that President Emmerson Mnangagwa deemed the arrangement was "skewed".
A government spokesperson later stated that the US was requesting biological samples for scientific study and commercial gain while was unwilling to guarantee the benefits from future treatments.
"We are forced to start the difficult and regrettable task of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had donated more than $1.9bn in health funding to Zimbabwe during the past twenty years.
A medical body in Zimbabwe has urged further talks to reach a deal acceptable to all parties so the country's vital HIV treatment initiative can be sustained.
Broader Background
This development follows a comparable situation in Kenya, where a court halted a related deal with the US following legal challenges were filed about the security of Kenyans' health data.
Since resuming the presidency recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had administered assistance for the American government, but Trump claimed its expenditure was "inefficient" and his government was pursuing direct bilateral deals to enhance openness and responsibility.
As per reports, 16 nations in Africa have so far agreed to these new health pacts, constituting more than $18.3bn in committed funds.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million men, women and children currently on HIV treatment via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"The proposal required Zimbabwe to surrender its genetic material and health information for a long time, with no equivalent assurance of benefiting from any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that provided information," he stated.
"Put simply, our nation would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be accessible to our population should a new pandemic emerge."
National Interest and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were undermining systems previously established through the international health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system designed to manage future global health emergencies.
"This framework is intended to guarantee that when a nation provides its samples, the resulting advantages – including medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to develop them."
These objections regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage continued discussions with our US partners on how subsequent co-operation could be arranged in a way that respects the sovereignty and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the official position, but urged that negotiations need to persist considering much of the nation's HIV programmes relied on international support.
"If specific concerns exist, such as those involving data governance or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," it commented.
This impasse underscores the ongoing challenges between receiving crucial foreign assistance and safeguarding a country's data in an increasingly interconnected world.